Evidence map›Paper›PMID 34419305›Full record

ArticleVaccine2021

Vaccine preventable diseases surveillance in Nepal: How much does it cost?

Xiao Xian Huang, Anindya Sekhar Bose, Binod Prasad Gupta, Pasang Rai, Sudhir Joshi, Jhalak Sharma Gautam, Bhim Singh Tinkari, Jos Vandelaer, Adam L Cohen, Minal K Patel

Abstract read
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiao Xian HuangImmunization, Vaccines, and Biologicals, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland. Electronic address: xhuang@who.int.
Anindya Sekhar BoseWorld Health Organization Country Office for Nepal, United Nations House, Pulchowk, Lalitpur, Nepal. Electronic address: bosea@who.int.
Binod Prasad GuptaWorld Health Organization Country Office for Nepal, United Nations House, Pulchowk, Lalitpur, Nepal.
Pasang RaiWorld Health Organization Country Office for Nepal, United Nations House, Pulchowk, Lalitpur, Nepal. Electronic address: Raip@who.int.
Sudhir JoshiWorld Health Organization Regional Office for South-East Asia, World Health House, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi 110 002, India. Electronic address: joshisu@who.int.
Jhalak Sharma GautamFamily Welfare Division, Department of Health Services, Govt. of Nepal, Nepal.
Bhim Singh TinkariFamily Welfare Division, Department of Health Services, Govt. of Nepal, Nepal.
Jos VandelaerWorld Health Organization Regional Office for South-East Asia, World Health House, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi 110 002, India. Electronic address: vandelaerjo@who.int.
Adam L CohenImmunization, Vaccines, and Biologicals, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland. Electronic address: dvj1@cdc.gov.
Minal K PatelImmunization, Vaccines, and Biologicals, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland. Electronic address: patelm@who.int.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Assessing the cost of vaccine preventable diseases (VPD) surveillance is becoming more important in the context of the Global Polio Eradication Initiative (GPEI) funding transition, since GPEI support to polio surveillance helped the incremental building of VPD surveillance systems in many countries, including low income countries such as Nepal. However, there is limited knowledge on the cost of conducting VPD surveillance, especially the national cost for surveillance of multiple vaccine-preventable diseases. The current study sought to calculate the economic and financial costs of Nepal's comprehensive VPD surveillance systems from July 2016 to July 2017. At thecentral level, all surveillance units were included in the sample. At sub-national level, a purposive sampling strategy was used to select a representative sample from locations involved in conducting surveillance. The sub-national sample costs were extrapolated to the nationwide VPD surveillance system. Nepal's total annual economic cost of VPD surveillance was USD 4.81 million or USD 0.18 per capita, while the total financial cost was USD 4.38 million or USD 0.16 per capita. Government expenditures accounted for 56% of the total economic cost, and World Health Organization accounting for 44%. The biggest cost driver was personnel accounting for 51% of the total economic cost. WHO supported trained surveillance personnel through donor funding, mainly from Global Polio Eradication Initiative. As a polio transition priority country, Nepal will need to make strategic choices to fully self-finance or seek full donor support or a mixed-financing model as polio program funding diminishes.

Indexed as

PoliomyelitisVaccine-Preventable DiseasesHealth ExpendituresHumansNepalWorld Health OrganizationCostCountry studyNepalPolio transitionSurveillanceVaccine preventable diseases

Identifiers

PMID34419305
PMCPMC8494117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.